Proton Therapy Pediatric denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for proton therapy pediatric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Pediatric Proton Therapy as Not FDA-Approved

This denial category is frequently the result of a misapplication of regulatory terminology. Proton beam therapy delivery systems are FDA-cleared medical devices; the "not FDA-approved" label in a coverage denial for a radiation service generally does not mean the technology lacks regulatory clearance. Instead, it often reflects the plan's clinical policy language around whether a specific application of proton therapy — for a particular diagnosis, histology, or anatomical site — is considered established rather than investigational under the plan's own evidence review. The distinction between FDA device clearance and a plan's internal evidence standard is important and should be addressed directly in the appeal.

## Why This Denial Is Appealable

Because proton therapy equipment is FDA-cleared and the treatment is delivered by licensed radiation oncologists under standard oncologic practice, a denial asserting the treatment is "not FDA-approved" is often factually contestable on its face. The appeal should request the precise clinical basis for this characterization — specifically, whether Aetna is asserting a lack of FDA device clearance (which is verifiable), or whether it is applying a plan-defined evidence standard under a policy that uses "not FDA-approved" as shorthand for investigational status. Clarifying this distinction is the first step in structuring an effective response.

## Federal Appeal Framework

• Internal appeal: File within 180 days. Request the clinical policy bulletin and the specific policy provision cited as the basis for the not-FDA-approved determination.
• External review (ACA §2719): Available after internal denial. An IRO can assess whether the plan's characterization of the treatment is consistent with the medical evidence.
• ERISA §503: The plan must identify the specific plan provision and clinical guideline relied upon; use this to expose whether the denial conflates regulatory status with plan-defined investigational criteria.
• Expedited review: Request if treatment delay would jeopardize the child's health.
• External review window: Initiate within four months of the final internal denial.

## Documentation to Gather

• FDA clearance documentation: Obtain and submit documentation of the FDA clearance status of proton beam therapy equipment to directly rebut a regulatory-basis denial.
• Radiation oncologist's letter: Should clarify that proton therapy is delivered using FDA-cleared equipment by licensed practitioners and address whether the plan's policy criteria are met for this indication.
• Diagnosis and treatment plan: Full oncologic workup, staging, tumor location documentation, and the treating team's rationale for selecting proton therapy.
• Applicable professional society guidance: Reference the relevant guideline organization (e.g., ASTRO) generically to situate the treatment within recognized clinical practice.
• Dosimetric comparison: Treatment-planning comparison supporting the clinical rationale for proton over photon therapy for this patient.

## Criteria-Mapping Structure

Request Aetna's clinical policy bulletin for proton beam therapy and read the "not FDA-approved" or "investigational" criteria carefully. Determine whether Aetna is applying a specific evidence standard (e.g., randomized trial data) or a regulatory standard. Address each requirement the policy actually imposes, with specific chart evidence and documentation for each point. If the denial is based on a policy that uses investigational criteria, treat this appeal as equivalent to an experimental denial and map the evidence accordingly.